Anlotinib and Bemocizumab for Early Esophageal Cancer
Part of Cancer, Digestive system clinical trials.
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–70 years old
- You have esophageal squamous cell carcinoma (confirmed by biopsy) that is stage II–IIIB, with no spread to distant organs
- You have never received chemotherapy or radiation for esophageal cancer
- Your overall health is good enough to tolerate treatment (ECOG score 0–1, meaning you can do most daily activities)
- Your heart, lungs, liver, kidneys, and thyroid function are basically normal
- You are willing to use birth control during and for 8 weeks after the trial, and to return for regular check-ups and blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial tests whether combining two immunotherapy drugs (which boost your immune system to fight cancer) with a standard chemotherapy drug before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if this approach shrinks the tumor and helps you live longer.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial is testing a combination of two drugs (cadonilimab and anlotinib) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.